Neoadjuvant Treatment Modalities in Esophageal Cancer

Esophageal cancer is the most prevalent cancer globally with poor survival outcome. The prognosis with surgery alone is poor, accounting for 30-40% of overall survival at 5 year. Either neoadjuvant chemotherapy (nCT) or chemoradiotherapy (nCRT) has been shown as efficatious therapy to improve patients outcomes in esophageal or esophagogastric junction cancer as compared with surgery alone. The purpose of this study was to explore the optimal neoadjuvant treatment modalities including PD-1/PD-L1 antibody or targeted drug for patients with esophageal or esophagogastric junction cancer.

Trial Details

NCT ID
NCT04821843
Phase
PHASE3
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • Platinum based chemotherapy
  • Paclitaxel based chemotherapy
  • Radiotherpay
  • Surgery
  • Immunotherapy
  • 5-FU Analog based chemotherpay
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • ≥18 years;
  • Esophageal or Esophagogastric cancer;
  • Histologically proven squamous cell carcinoma or adenocarcinoma in patients staged as I-IVa (AJCC 8th);
  • Primary treatment performed in Cancer Hospital, Chinese Academy of Medical Sciences;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →